JAGSNPHARM.BOJAGSNPHARM.BO
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +29.16% | +56.72% | +34.66% | +23.07% | -0.30% |
| Gross Profit Growth | -26.35% | +0.00% | +214.90% | +132.95% | +73.73% |
| EBITDA Growth | +68.62% | +598.66% | +63.73% | +102.91% | +8.48% |
| Operating Income Growth | +36.92% | +349.77% | +182.83% | +29.39% | +0.75% |
| Net Income Growth | +53.36% | +707.22% | +85.49% | +102.57% | +9.73% |
| EPS Growth | -39.65% | +690.00% | +81.48% | +97.53% | +9.30% |
| EPS Diluted Growth | -40.35% | +703.39% | +88.46% | +105.19% | +10.00% |
| Weighted Average Shares Growth | +1.96% | +2.69% | +2.21% | +2.00% | +0.16% |
| Weighted Average Shares Diluted Growth | +2.92% | +0.14% | -0.33% | -1.02% | -0.25% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -25.80% | +0.00% | +20.32% | +0.00% | +15.81% |
| Inventory Growth | -16.78% | +0.00% | +1.35% | +0.00% | -5.66% |
| Asset Growth | +23.30% | +0.00% | +28.18% | +0.00% | +15.81% |
| Book Value per Share Growth | +14.12% | +13.30% | +25.27% | +25.52% | +28.08% |
| Debt Growth | +5.41% | +0.00% | +3.33% | +0.00% | -9.97% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +4.55% | -100.00% | +75.64% | -100.00% | -100.00% |